Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,152 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company's stock, valued at $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Stock Down 26.1 %

Shares of NYSE HIMS traded down $17.32 during trading hours on Friday, hitting $49.10. 87,881,723 shares of the stock were exchanged, compared to its average volume of 17,758,602. The company has a market cap of $10.73 billion, a PE ratio of 111.58 and a beta of 1.35. Hims & Hers Health, Inc. has a 12 month low of $9.25 and a 12 month high of $72.98. The firm has a fifty day moving average price of $34.66 and a 200-day moving average price of $25.48.

Analyst Upgrades and Downgrades

Several research firms recently commented on HIMS. Bank of America raised their price target on shares of Hims & Hers Health from $18.00 to $21.00 and gave the stock an "underperform" rating in a research note on Thursday. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday. TD Cowen reissued a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their target price for the company from $42.00 to $60.00 in a research report on Tuesday. Finally, BTIG Research began coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Two analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.53.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently made changes to their positions in HIMS. Vanguard Group Inc. grew its stake in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Finally, State Street Corp raised its position in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after purchasing an additional 206,078 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.